On July 29, 2020 AskAt Inc. (AskAt) received a notice of allowance dated July 21, 2020 from the Brazilian National Institute of Industrial Property (NIIP) in connection with Application No. PI1014174-0, a use patent for AskAt’s EP4 antagonists in the treatment of epithelial cancers (Press release, AskAt, JUL 29, 2020, View Source [SID1234562479]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clinical Development of Grapiprant for Cancer Immunotherapy Ikena Oncology (formally Kyn Therapeutics, a parent company of Arrys Therapeutics, which licensed worldwide rights to AskAt’s EP4 antagonists except in China) and Ningbo NewBay Pharmaceutical Co. Ltd. (a subsidiary of Ningbo Tai Kang Medical Technology Co. Ltd., which licensed AskAt’s EP4 antagonists for cancer use in China), are currently conducting clinical studies of grapiprant (IK-007/RMX1002) in the U.S. and China, respectively.